542 related articles for article (PubMed ID: 11483764)
1. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.
Henke A; Zell R; Ehrlich G; Stelzner A
J Virol; 2001 Sep; 75(17):8187-94. PubMed ID: 11483764
[TBL] [Abstract][Full Text] [Related]
2. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.
Henke A; Jarasch N; Martin U; Wegert J; Wildner A; Zell R; Wutzler P
Int J Med Microbiol; 2008 Jan; 298(1-2):127-34. PubMed ID: 17897883
[TBL] [Abstract][Full Text] [Related]
3. The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice.
Schmidtke M; Merkle I; Klingel K; Hammerschmidt E; Zautner AE; Wutzler P
J Med Virol; 2007 Sep; 79(9):1334-42. PubMed ID: 17607777
[TBL] [Abstract][Full Text] [Related]
4. Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas.
Pinkert S; Pryshliak M; Pappritz K; Knoch K; Hazini A; Dieringer B; Schaar K; Dong F; Hinze L; Lin J; Lassner D; Klopfleisch R; Solimena M; Tschöpe C; Kaya Z; El-Shafeey M; Beling A; Kurreck J; Van Linthout S; Klingel K; Fechner H
Cardiovasc Res; 2020 Aug; 116(10):1756-1766. PubMed ID: 31598635
[TBL] [Abstract][Full Text] [Related]
5. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.
Slifka MK; Pagarigan R; Mena I; Feuer R; Whitton JL
J Virol; 2001 Mar; 75(5):2377-87. PubMed ID: 11160741
[TBL] [Abstract][Full Text] [Related]
6. Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice.
Glück B; Schmidtke M; Merkle I; Stelzner A; Gemsa D
J Mol Cell Cardiol; 2001 Sep; 33(9):1615-26. PubMed ID: 11549341
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis.
Horwitz MS; La Cava A; Fine C; Rodriguez E; Ilic A; Sarvetnick N
Nat Med; 2000 Jun; 6(6):693-7. PubMed ID: 10835688
[TBL] [Abstract][Full Text] [Related]
8. Direct interferon-gamma-mediated protection caused by a recombinant coxsackievirus B3.
Henke A; Zell R; Martin U; Stelzner A
Virology; 2003 Oct; 315(2):335-44. PubMed ID: 14585336
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the protective capability of a recombinant coxsackievirus B3 variant expressing interferon-gamma.
Henke A; Jarasch N; Martin U; Zell R; Wutzler P
Viral Immunol; 2008 Mar; 21(1):38-48. PubMed ID: 18355121
[TBL] [Abstract][Full Text] [Related]
10. Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis.
Gauntt CJ; Paque RE; Trousdale MD; Gudvangen RJ; Barr DT; Lipotich GJ; Nealon TJ; Duffey PS
Infect Immun; 1983 Feb; 39(2):851-64. PubMed ID: 6299950
[TBL] [Abstract][Full Text] [Related]
11. IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-gamma and macrophage and neutrophil populations in the heart.
Fairweather D; Frisancho-Kiss S; Yusung SA; Barrett MA; Davis SE; Steele RA; Gatewood SJ; Rose NR
J Immunol; 2005 Jan; 174(1):261-9. PubMed ID: 15611248
[TBL] [Abstract][Full Text] [Related]
12. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis.
Yuan J; Liu Z; Lim T; Zhang H; He J; Walker E; Shier C; Wang Y; Su Y; Sall A; McManus B; Yang D
Circ Res; 2009 Mar; 104(5):628-38. PubMed ID: 19168435
[TBL] [Abstract][Full Text] [Related]
13. Gr-1+ Cells Other Than Ly6G+ Neutrophils Limit Virus Replication and Promote Myocardial Inflammation and Fibrosis Following Coxsackievirus B3 Infection of Mice.
Xu D; Wang P; Yang J; Qian Q; Li M; Wei L; Xu W
Front Cell Infect Microbiol; 2018; 8():157. PubMed ID: 29868513
[TBL] [Abstract][Full Text] [Related]
14. Coxsackievirus B3-induced chronic myocarditis in mouse: use of whole blood culture to study the activation of TNF alpha-producing cells.
Hober D; Andreoletti L; Shen L; Copin MC; Desmidt A; Wattré P
Microbiol Immunol; 1996; 40(11):837-45. PubMed ID: 8985939
[TBL] [Abstract][Full Text] [Related]
15. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis.
Yuan J; Yu M; Lin QW; Cao AL; Yu X; Dong JH; Wang JP; Zhang JH; Wang M; Guo HP; Cheng X; Liao YH
J Immunol; 2010 Oct; 185(7):4004-10. PubMed ID: 20802148
[TBL] [Abstract][Full Text] [Related]
16. Colchicine aggravates coxsackievirus B3 infection in mice.
Smilde BJ; Woudstra L; Fong Hing G; Wouters D; Zeerleder S; Murk JL; van Ham M; Heymans S; Juffermans LJ; van Rossum AC; Niessen HW; Krijnen PA; Emmens RW
Int J Cardiol; 2016 Aug; 216():58-65. PubMed ID: 27140338
[TBL] [Abstract][Full Text] [Related]
17. Secondary heterotypic versus homotypic infection by Coxsackie B group viruses: impact on early and late histopathological lesions and virus genome prominence.
Yu JZ; Wilson JE; Wood SM; Kandolf R; Klingel K; Yang D; McManus BM
Cardiovasc Pathol; 1999; 8(2):93-102. PubMed ID: 10724506
[TBL] [Abstract][Full Text] [Related]
18. The outcome of coxsackievirus B3-(CVB3-) induced myocarditis is influenced by the cellular immune status.
Leipner C; Grün K; Borchers M; Stelzner A
Herz; 2000 May; 25(3):245-8. PubMed ID: 10904846
[TBL] [Abstract][Full Text] [Related]
19. Astragaloside IV exerts antiviral effects against coxsackievirus B3 by upregulating interferon-gamma.
Zhang Y; Zhu H; Huang C; Cui X; Gao Y; Huang Y; Gong W; Zhao Y; Guo S
J Cardiovasc Pharmacol; 2006 Feb; 47(2):190-5. PubMed ID: 16495755
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of pathogenesis of coxsackievirus B3 infections in mice by exogenous administration of interleukin-1 and interleukin-2.
Huber SA; Polgar J; Schultheiss P; Schwimmbeck P
J Virol; 1994 Jan; 68(1):195-206. PubMed ID: 8254729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
